Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

What’s on CS111: The final covers programming basics, data structures, algorithms, recursion, and problem-solving, often through multiple-choice and coding questions. How to prepare: Review lectures ...

Abstract: Basic Programming Practice (BPP), as an introductory course for computer science majors, aims to enable students to have basic programming skills and lay a foundation for subsequent advanced ...

From stock market analysis to AI-powered predictions, explore projects that boost your portfolio Whether beginner or expert, these R projects can accelerate your career in 2026 Data science today ...

So, you want to get better at Java coding? That’s awesome. The thing is, just watching videos or reading books only gets you so far. You really need to get your hands dirty and write some code.

So, you want to get better at Java coding, huh? It’s a pretty popular language, and honestly, getting some hands-on practice is the best way to really learn it. Luckily, there are a bunch of places ...

Learn how to use advanced techniques like short-circuiting, parallel execution, virtual threads, and stream gatherers to maximize Java stream performance. My recent Java Stream API tutorial introduced ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...